Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36 mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

No significant benefit seen for HEPA versus sham filter for diastolic BP or among those with normal systolic BP.